Anna Brännbäck
YOU?
Author Swipe
View article: Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma
Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma Open
Objectives Adjuvant pembrolizumab has improved overall survival after surgery for clear cell renal cell carcinoma (ccRCC) with an intermediate‐high and high risk of recurrence according to the inclusion criteria of Keynote‐564 study, but n…